Crossmark

Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis

Published Online: 2023-03-04

Published Print: 2023-04

Authors

Liu, Kun

Zhu, Youwen

Zhou, Yangying

Zhu, Hong https://orcid.org/0000-0002-3659-8070
Funding

Funding for this research was provided by:

Natural Science Foundation of Hunan Province (202JJ40851)

Xiangya Hospital, Central South University (2021Q16, 2016L06)
License Information

Text and Data Mining valid from 2023-03-04

Version of Record valid from 2023-03-04
More Information

Article History

Received: 20 November 2022

Accepted: 17 February 2023

First Online: 4 March 2023

Document is current